Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Novel Chitosan Nanoparticles Loaded with Methotrexate for Topical Treatment of Psoriasis

Author(s): Nusaiba K. Al-Nemrawi*, Areej S. Khafajah and Karem H. Alzoubi

Volume 11, Issue 5, 2023

Published on: 09 June, 2023

Page: [460 - 474] Pages: 15

DOI: 10.2174/2211738511666230502154110

Price: $65

conference banner
Abstract

Aims: In this work, CS NPs were prepared by the ionic gelation method and encapsulated with MTX to treat psoriasis dermally.

Background: A major drawback of using MTX to treat psoriasis is its limited diffusion through the skin, which may cause insufficient penetration of MTX into the basal layer of the epidermis, where psoriatic cells are generated.

Objective: Nanoparticles have been used to enhance MTX diffusion through the skin. The system prepared in this work is expected to direct the drug to psoriasis cells by enhancing the drug diffusion through the skin, which will increase the amount of the drug reaching the epidermis. This is expected to enhance the effectiveness of the drug and to decrease its systemic side effects.

Methods: Five formulations of Chitosan nanoparticles were prepared and loaded with Methotrexate using the ionic gelation technique. Particle size, dispersity, charge, loading capacity and encapsulation efficacy were measured. Characterization of prepared nanoparticles was conducted to confirm the formation of CS-NPs, successful encapsulation of MTX and its compatibility with other formulation components. In vitro drug release from CS-NPs, its permeation and accumulation in rats’ skin were explored. Finally, the anti-psoriatic activity was assessed using the “mouse tail model.”

Results: The results showed that the sizes ranged from 132.13 ± 0.70 to 300.60 ± 4.81 nm, where SEM demonstrated the spherical and uniform distribution of the NPs. The surface charge of all NPs was highly positive and ranged from 20.22 ± 1.10 to 30.90 ± 0.70 mV. Further, the EE% and LC% of the nanoparticles were in the range of 77.72%-92.70% and 17.90%-21.81%, respectively. in vitro, the release of methotrexate from the nanoparticles was sustained. Additionally, both the permeation and retention of drugs within the skin were enhanced significantly using this system. Eventually, orthokeratosis% and drug activity% showed significant superiority of MTX-CS NPs over the free drug in treating psoriasis in model mice.

Conclusion: In conclusion, MTX-CS NPs can be used to enhance the treatment of psoriasis topically.

« Previous Next »
Graphical Abstract

[1]
Nasir A. Nanotechnology and dermatology: Part I—potential of nanotechnology. Clin Dermatol 2010; 28(4): 458-66.
[http://dx.doi.org/10.1016/j.clindermatol.2009.06.005] [PMID: 20620764]
[2]
Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58(6): 1031-42.
[http://dx.doi.org/10.1016/j.jaad.2008.01.006] [PMID: 18313171]
[3]
Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60(1): 120-4.
[http://dx.doi.org/10.1016/j.jaad.2008.06.041] [PMID: 19103363]
[4]
Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology 2021; 458: 152840.
[http://dx.doi.org/10.1016/j.tox.2021.152840] [PMID: 34175381]
[5]
Biswasroy P, Pradhan D, Kar B, Ghosh G, Rath G. Recent advancement in topical nanocarriers for the treatment of psoriasis. AAPS PharmSciTech 2021; 22(5): 164.
[http://dx.doi.org/10.1208/s12249-021-02057-z] [PMID: 34041632]
[6]
Giri BR, Kim JS, Park JH, et al. Improved bioavailability and high photostability of methotrexate by spray-dried surface-attached solid dispersion with an aqueous medium. Pharmaceutics 2021; 13(1): 111.
[http://dx.doi.org/10.3390/pharmaceutics13010111] [PMID: 33467157]
[7]
Khan A, Qadir A, Ali F, Aqil M. Phytoconstituents based nanomedicines for the management of psoriasis. J Drug Deliv Sci Technol 2021; 64: 102663.
[http://dx.doi.org/10.1016/j.jddst.2021.102663]
[8]
Bessar H, Venditti I, Benassi L, et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf B Biointerfac 2016; 141: 141-7.
[http://dx.doi.org/10.1016/j.colsurfb.2016.01.021] [PMID: 26852097]
[9]
Pinto MF, Moura CC, Nunes C, Segundo MA, Costa Lima SA, Reis S. A new topical formulation for psoriasis: Development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm 2014; 477(1-2): 519-26.
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.067] [PMID: 25445970]
[10]
Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004; 100(1): 5-28.
[http://dx.doi.org/10.1016/j.jconrel.2004.08.010] [PMID: 15491807]
[11]
Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces 2012; 90: 21-7.
[http://dx.doi.org/10.1016/j.colsurfb.2011.09.042] [PMID: 22014934]
[12]
Dyer AM, Hinchcliffe M, Watts P, et al. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res 2002; 19(7): 998-1008.
[http://dx.doi.org/10.1023/A:1016418523014] [PMID: 12180553]
[13]
Sun Y, Wan A. Preparation of nanoparticles composed of chitosan and its derivatives as delivery systems for macromolecules. J Appl Polym Sci 2007; 105(2): 552-61.
[http://dx.doi.org/10.1002/app.26038]
[14]
Wu J, Wang Y, Yang H, Liu X, Lu Z. Preparation and biological activity studies of resveratrol loaded ionically cross-linked chitosan-TPP nanoparticles. Carbohydr Polym 2017; 175: 170-7.
[http://dx.doi.org/10.1016/j.carbpol.2017.07.058] [PMID: 28917853]
[15]
Guo X, Zhuang Q, Ji T, et al. Multi-functionalized chitosan nanoparticles for enhanced chemotherapy in lung cancer. Carbohydr Polym 2018; 195: 311-20.
[http://dx.doi.org/10.1016/j.carbpol.2018.04.087] [PMID: 29804982]
[16]
Al-Nemrawi N, Hameedat F, Al-Husein B, Nimrawi S. Photolytic controlled release formulation of methotrexate loaded in chitosan/TiO2 nanoparticles for breast cancer. Pharmaceuticals (Basel) 2022; 15(2): 149.
[http://dx.doi.org/10.3390/ph15020149] [PMID: 35215259]
[17]
Al-Nemrawi NK, Altawabeyeh RM, Darweesh RS. Preparation and characterization of docetaxel-PLGA nanoparticles coated with folic acid-chitosan conjugate for cancer treatment. J Pharm Sci 2022; 111(2): 485-94.
[http://dx.doi.org/10.1016/j.xphs.2021.10.034] [PMID: 34728172]
[18]
Wang Y, Fu S, Lu Y, et al. Chitosan/hyaluronan nanogels co-delivering methotrexate and 5-aminolevulinic acid: A combined chemo-photodynamic therapy for psoriasis. Carbohydr Polym 2022; 277: 118819.
[http://dx.doi.org/10.1016/j.carbpol.2021.118819] [PMID: 34893236]
[19]
Barbosa AI, Costa Lima SA, Reis S. Development of methotrexate loaded fucoidan/chitosan nanoparticles with anti-inflammatory potential and enhanced skin permeation. Int J Biol Macromol 2019; 124: 1115-22.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.12.014] [PMID: 30521895]
[20]
Asad MI, Khan D, Rehman A, Elaissari A, Ahmed N. Development and in vitro/in vivo evaluation of pH-sensitive polymeric nanoparticles loaded hydrogel for the management of psoriasis. Nanomaterials (Basel) 2021; 11(12): 3433.
[http://dx.doi.org/10.3390/nano11123433] [PMID: 34947782]
[21]
Mohammadi-Samani S, Miri R, Salmanpour M, Khalighian N, Sotoudeh S, Erfani N. Preparation and assessment of chitosan-coated superparamagnetic Fe3O4 nanoparticles for controlled delivery of methotrexate. Res Pharm Sci 2013; 8(1): 25-33.
[PMID: 24459473]
[22]
Al-Nemrawi NK, Alsharif SSM, Alzoubi KH, Alkhatib RQ. Preparation and characterization of insulin chitosan-nanoparticles loaded in buccal films. Pharm Dev Technol 2019; 24(8): 967-74.
[http://dx.doi.org/10.1080/10837450.2019.1619183] [PMID: 31092092]
[23]
Garg NK, Sharma G, Singh B, Nirbhavane P, Katare OP. Quality by design (QbD)-based development and optimization of a simple, robust RP-HPLC method for the estimation of methotrexate. J Liq Chromatogr Relat Technol 2015; 38(17): 1629-37.
[http://dx.doi.org/10.1080/10826076.2015.1087409]
[24]
Al-Nemrawi NK, Alshraiedeh NAH, Zayed AL, Altaani BMJP. Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis. Pharmaceuticals 2018; 11(1): 28.
[http://dx.doi.org/10.3390/ph11010028]
[25]
Amarachinta PR, Sharma G, Samed N, Chettupalli AK, Alle M, Kim J-C. Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect. J Nanobiotechnology 2021; 19(1): 1-15.
[PMID: 33397416]
[26]
Gouda R, Baishya H, Qing Z. Application of mathematical models in drug release kinetics of carbidopa and levodopa ER tablets. J Dev Drugs 2017; 6(02): 1-8.
[27]
Bhatia A, Raza K, Singh B, Katare OP. Phospholipid-based formulation with improved attributes of coal tar. J Cosmet Dermatol 2009; 8(4): 282-8.
[http://dx.doi.org/10.1111/j.1473-2165.2009.00468.x] [PMID: 19958432]
[28]
Bhatia A, Singh B, Wadhwa S, Raza K, Katare OP. Novel phospholipid-based topical formulations of tamoxifen: Evaluation for antipsoriatic activity using mouse-tail model. Pharm Dev Technol 2014; 19(2): 160-3.
[http://dx.doi.org/10.3109/10837450.2013.763260] [PMID: 23369039]
[29]
Zhao Z, Ukidve A, Krishnan V, Mitragotri S. Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers. Adv Drug Deliv Rev 2019; 143: 3-21.
[http://dx.doi.org/10.1016/j.addr.2019.01.002] [PMID: 30639257]
[30]
Giannavola C, Bucolo C, Maltese A, et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003; 20(4): 584-90.
[http://dx.doi.org/10.1023/A:1023290514575] [PMID: 12739765]
[31]
Peltonen L. Practical guidelines for the characterization and quality control of pure drug nanoparticles and nano-cocrystals in the pharmaceutical industry. Adv Drug Deliv Rev 2018; 131: 101-15.
[http://dx.doi.org/10.1016/j.addr.2018.06.009] [PMID: 29920294]
[32]
Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018; 10(2): 57.
[http://dx.doi.org/10.3390/pharmaceutics10020057] [PMID: 29783687]
[33]
Loutfy SA, El-Din HMA, Elberry MH, Allam NG, Hasanin M, Abdellah AM. Synthesis, characterization and cytotoxic evaluation of chitosan nanoparticles: In vitro liver cancer model. Adv Nat Sci: Nanosci Nanotechnol 2016; 7(3): 035008.
[34]
Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan–TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces 2005; 44(2-3): 65-73.
[http://dx.doi.org/10.1016/j.colsurfb.2005.06.001] [PMID: 16024239]
[35]
Raghavendra Naveen N, Kurakula M, Gowthami B. Process optimization by response surface methodology for preparation and evaluation of methotrexate loaded chitosan nanoparticles. Mater Today Proc 2020; 33: 2716-24.
[http://dx.doi.org/10.1016/j.matpr.2020.01.491]
[36]
Arsalani N, Nezhad-Mokhtari P, Jabbari E. Microwave-assisted and one-step synthesis of PEG passivated fluorescent carbon dots from gelatin as an efficient nanocarrier for methotrexate delivery. Artif Cells Nanomed Biotechnol 2019; 47(1): 540-7.
[http://dx.doi.org/10.1080/21691401.2018.1562460] [PMID: 30829085]
[37]
Teja S, Damodharan N. 23 full factorial model for particle size optimization of methotrexate loaded chitosan nanocarriers: A design of experiments (DoE) Approach. BioMed Res Int 2018; 2018: 7834159.
[38]
Agrawal YO, Mahajan UB, Mahajan HS, Ojha S. Methotrexate-loaded nanostructured lipid carrier gel alleviates imiquimod-induced psoriasis by moderating inflammation: Formulation, optimization, characterization, in-vitro and in-vivo studies. Int J Nanomedicine 2020; 15: 4763-78.
[http://dx.doi.org/10.2147/IJN.S247007] [PMID: 32753865]
[39]
Silva SM, Braga CR, Fook MV, Raposo CM, Carvalho LH, Canedo EL. Application of infrared spectroscopy to analysis of chitosan/clay nanocomposites. In: Infrared Spectroscopy. Intechopen 2012.
[40]
Jingou J, Shilei H, Weiqi L, Danjun W, Tengfei W, Yi X. Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids Surf B Biointerfaces 2011; 83(1): 103-7.
[http://dx.doi.org/10.1016/j.colsurfb.2010.11.005] [PMID: 21112190]
[41]
Obaidat RM, Tashtoush BM, Bayan MFT, Al Bustami RT, Alnaief M. Drying using supercritical fluid technology as a potential method for preparation of chitosan aerogel microparticles. AAPS PharmSciTech 2015; 16(6): 1235-44.
[http://dx.doi.org/10.1208/s12249-015-0312-2] [PMID: 25761387]
[42]
de Oliveira AR, Molina EF, de Castro Mesquita P, et al. Structural and thermal properties of spray-dried methotrexate-loaded biodegradable microparticles. J Therm Anal Calorim 2013; 112(2): 555-65.
[http://dx.doi.org/10.1007/s10973-012-2580-3]
[43]
Azevedo JR, Sizilio RH, Brito MB, et al. Physical and chemical characterization insulin-loaded chitosan-TPP nanoparticles. J Therm Anal Calorim 2011; 106(3): 685-9.
[http://dx.doi.org/10.1007/s10973-011-1429-5]
[44]
Musmade KP, Deshpande PB, Musmade PB, et al. Methotrexate-loaded biodegradable nanoparticles: Preparation, characterization and evaluation of its cytotoxic potential against U-343 MGa human neuronal glioblastoma cells. Bull Mater Sci 2014; 37(4): 945-51.
[http://dx.doi.org/10.1007/s12034-014-0030-5]
[45]
Li F, Wu H, Zhang H, Li F, Gu C, Yang Q. Antitumor drug Paclitaxel-loaded pH-sensitive nanoparticles targeting tumor extracellular pH. Carbohydr Polym 2009; 77(4): 773-8.
[http://dx.doi.org/10.1016/j.carbpol.2009.02.029]
[46]
Nedelcu RI, Balaban M, Turcu G, et al. Efficacy of methotrexate as anti inflammatory and anti proliferative drug in dermatology: Three case reports. Exp Ther Med 2019; 18(2): 905-10.
[http://dx.doi.org/10.3892/etm.2019.7511] [PMID: 31384322]
[47]
Al-Kassas R, Wen J, Cheng AEM, Kim AMJ, Liu SSM, Yu J. Transdermal delivery of propranolol hydrochloride through chitosan nanoparticles dispersed in mucoadhesive gel. Carbohydr Polym 2016; 153: 176-86.
[http://dx.doi.org/10.1016/j.carbpol.2016.06.096] [PMID: 27561485]
[48]
Hatem S, Elkheshen SA, Kamel AO, et al. Functionalized chitosan nanoparticles for cutaneous delivery of a skin whitening agent: An approach to clinically augment the therapeutic efficacy for melasma treatment. Drug Deliv 2022; 29(1): 1212-31.
[http://dx.doi.org/10.1080/10717544.2022.2058652] [PMID: 35403519]
[49]
Bosman B, Matthiesen T, Hess V, Friderichs E. A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test. Skin Pharmacol Physiol 1992; 5(1): 41-8.
[http://dx.doi.org/10.1159/000211016] [PMID: 1575981]
[50]
Tan Q, Liu W, Guo C, Zhai G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomedicine 2011; 6: 1621-30.
[PMID: 21904452]
[51]
Matos BN, Reis TA, Gratieri T, Gelfuso GM. Chitosan nanoparticles for targeting and sustaining minoxidil sulphate delivery to hair follicles. Int J Biol Macromol 2015; 75: 225-9.
[http://dx.doi.org/10.1016/j.ijbiomac.2015.01.036] [PMID: 25647618]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy